Kailera Therapeutics is trading 4.02% down now at $17.77 as biotechnology shares weaken and broader risk appetite fades.
- The biotechnology sector fell 4.03% on August 18, 2026, while the Nasdaq Composite declined 1.14%.
- Its August 12 report highlighted pipeline progress but showed a $111.3 million second-quarter net loss, which may be weighing on sentiment alongside sector pressure.